RSV Treatment
For acute RSV infection in children, treatment is primarily supportive care—there is no routine role for bronchodilators, corticosteroids, or ribavirin in otherwise healthy children with RSV bronchiolitis. 1
Acute Treatment Approach
What NOT to Use (Strong Evidence Against)
- Corticosteroids: Should NOT be used routinely 1
- Ribavirin: Should NOT be used routinely in children with bronchiolitis 1
- Bronchodilators: Not recommended routinely; may trial α- or β-adrenergic medications only if you can objectively document clinical improvement, otherwise discontinue 1
- Antibiotics: Only use if there are specific indicators of concurrent bacterial infection 1
- Chest physiotherapy: Should NOT be used routinely 1
Supportive Care Measures (What TO Do)
Oxygen therapy:
- Administer supplemental oxygen if SpO2 persistently falls below 90% in previously healthy infants
- Maintain SpO2 ≥90%
- Discontinue when SpO2 ≥90%, infant feeds well, and has minimal respiratory distress 1
- Critical caveat: Infants with hemodynamically significant heart/lung disease and premature infants require close monitoring during oxygen weaning 1
Hydration:
- Assess hydration status and oral intake ability
- Provide IV or nasogastric fluids for infants unable to maintain hydration orally 1, 2
Infection control:
- Hand decontamination before/after patient contact is the most important preventive measure
- Use alcohol-based rubs preferentially over antimicrobial soap 1
Prevention Strategies
Palivizumab Prophylaxis (Not Treatment)
High-risk infants eligible for prophylaxis receive palivizumab BEFORE RSV season, not as treatment for active infection. The 2009 AAP guidelines 3 specify:
Maximum 5 doses for:
- Infants <24 months with chronic lung disease requiring medical therapy (oxygen, bronchodilators, diuretics, corticosteroids) within 6 months before RSV season
- Infants <24 months with hemodynamically significant congenital heart disease requiring medical therapy
- Infants born ≤31 weeks 6 days gestation
- Certain infants with neuromuscular disease or airway abnormalities compromising secretion handling
Maximum 3 doses for:
- Premature infants 32 weeks 0 days through 34 weeks 6 days gestation with risk factors (attends childcare OR has siblings <5 years old) born within 3 months before or during RSV season—only until 90 days of age 3
Dosing: 15 mg/kg intramuscularly monthly during RSV season (typically November through March) 1
Important nuance: If an infant on prophylaxis develops breakthrough RSV infection, continue monthly doses until reaching the maximum number for their risk category 3
Special Populations: Immunocompromised Patients
For hematopoietic stem cell transplant (HSCT) recipients and leukemia patients, the approach differs significantly 4:
For RSV upper respiratory tract infection (URTID) in allogeneic HSCT patients with risk factors:
- Treat with aerosolized or systemic ribavirin PLUS IVIG to prevent progression to lower respiratory tract disease
For RSV lower respiratory tract infection (LRTID):
- Aerosolized ribavirin: 2g over 2 hours every 8 hours OR 6g over 18 hours daily for 7-10 days
- Alternative: Systemic ribavirin 10-30 mg/kg/day in 3 divided doses (oral preferred, IV if unable to take oral)
- May combine with IVIG or anti-RSV-enriched antibody preparations
- Monitor for adverse effects: hemolysis, abnormal liver function, declining renal function, bronchospasm, claustrophobia 4
Critical consideration: Defer conditioning therapy for patients with RSV respiratory tract infection planned for allogeneic HSCT 4
Emerging Therapies
Recent advances include new monoclonal antibodies with extended half-life and RSV vaccines for older adults and pregnant women (for passive infant protection), but these are preventive, not therapeutic interventions 5, 6. Specific antiviral treatment options for established RSV infection remain limited despite ongoing drug development 5, 7.